nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

01.12.2023 | editorial

Supportive management

verfasst von: Priv.-Doz. Dr. Christoph Minichsdorfer, PhD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Excerpt

The introduction of checkpoint inhibitor therapy and advances in targeted therapy have led to impressive improvements in the treatment of cancer patients. In the shadow of these developments, progress in supportive management of tumor and therapy-associated side effects is often underrated. …

Vorheriger Artikel Prostate cancer special—part 1

Nächster Artikel ASCO 2023: new treatment options in CNS tumors

Popov P. Challenges in prevention, early detection, and management of febrile Neutropenia in adult patients with solid tumors. memo. 2023; https://doi.org/10.1007/s12254-023-00909-x.CrossRef

Petrasch C, Marics P, Spanberger T. Management of malignant hypercalcemia in cancer patients—A short review. memo. 2023;16(4).

Heregger R, Keil F. EPO—benefits and harms in the treatment of anemia in cancer patients. memo. 2023; https://doi.org/10.1007/s12254-023-00902-4.CrossRef

Titel: Supportive management
verfasst von: Priv.-Doz. Dr. Christoph Minichsdorfer, PhD
Publikationsdatum: 01.12.2023
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 4/2023
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-023-00926-w

Springer Medizin Österreich

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2023

ASCO 2023: new treatment options in CNS tumors

Fifth-line HER2-directed therapy for metastatic adenocarcinoma of the gastroesophageal junction

ASCO update—hepatocellular carcinoma and cholangiocellular carcinoma

WNT3 and LEF1 as markers for diagnosis and survival prediction in chronic lymphocytic leukemia patients

Second-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma

Essential news from ASCO 2023 in primary resectable and advanced or metastatic pancreatic cancer